Clinical Trials Logo

Filter by:
NCT ID: NCT02919332 Withdrawn - Glioblastoma Clinical Trials

Delayed 18F-FDG PET/CT in Improving Visualization of Brain Tumors in Patients With Glioblastoma

Start date: June 8, 2016
Phase:
Study type: Observational

This clinical trial studies how well delayed fludeoxyglucose F-18 (18F-FDG) positron emission tomography (PET)/computed tomography (CT) works in improving visualization of brain tumors in patients with glioblastoma. Radiotracers such as 18F-FDG are highly taken up by tumors in the brain and are visualized using PET/CT. Increasing the interval of time between 18F-FDG administration and PET/CT scan may improve the visualization of brain tumors in patients with glioblastoma.

NCT ID: NCT02917148 Withdrawn - Acute GVH Disease Clinical Trials

MicroRNAs as Diagnostic and Predictive Biomarkers for Acute Graft Versus Host Disease

Start date: September 2016
Phase: N/A
Study type: Observational

The goal of this research proposal is to identify a miRNA expression profile as a biomarker to diagnose and predict acute graft versus host disease (aGVHD) in patients who undergo allogeneic transplantation. This biomarker, once identified, will need validation in larger cohorts.

NCT ID: NCT02915666 Withdrawn - Melanoma Clinical Trials

A Clinical Trial of Patients With Melanoma

Start date: October 2016
Phase: Phase 1
Study type: Interventional

This study is being done to find out if the combination of dabrafenib, trametinib and digoxin will lessen the side effects that you may experience and to measure your response and duration of response to the combination of drugs.

NCT ID: NCT02914327 Withdrawn - Cancer Clinical Trials

Safety and Activity of SNX-5422 Plus Ibrutinib in CLL

Start date: February 2, 2017
Phase: Phase 1
Study type: Interventional

SNX-5422 is a prodrug of SNX-2112, a potent, highly selective, small molecule inhibitor of the molecular chaperone heat shock protein 90 (HSP90). Hsp90 inhibitors may overcome ibrutinib resistance in Mantle cell lymphomas and this study will investigate whether the addition of SNX-5422 to an established dose of ibrutinib will result in the removal of mutated BTK from blood mononuclear cells and/or prevents or delays disease progression of subjects with CLL

NCT ID: NCT02913807 Withdrawn - Clinical trials for Free Tissue Transfer

Traditional Versus Computerized Mandibular Reconstruction

Start date: December 2016
Phase: N/A
Study type: Interventional

This study will test the accuracy of computerized custom mandibular reconstruction to traditional methods of mandibular reconstruction using a vascularized osteocutaneous fibula flap.

NCT ID: NCT02913742 Withdrawn - Clinical trials for Epilepsy, Temporal Lobe

The Utility of NIOM During LITT for Refractory MTLE

Start date: March 2017
Phase: N/A
Study type: Interventional

Mesial temporal lobe epilepsy (MTLE) is the most common cause of medication-resistant epilepsy in adults, and MRI-guided laser interstitial thermal therapy is a new approach to its surgical management; however, while LITT demonstrates fewer complications than traditional surgical techniques, it generates lower rates of seizure freedom. During traditional temporal lobectomy for MTLE, neurophysiologic intraoperative monitoring (NIOM) can be used to better identify epileptogenic tissue and guide resection. Our study proposes to investigate the utility of NIOM during LITT for MTLE. Subjects will be drawn from refractory mesial temporal lobe epilepsy patients determined to be candidates for LITT. During their LITT surgery, in addition to the placement of the stereotactic LITT probe, subjects will receive a second smaller stereotactic electrode for intraoperative monitoring of epileptic discharges before and after surgery. After surgery, at regularly scheduled follow-ups, patients will receive the Quality of Life in Epilepsy questionnaire (QOLIE-31-P), in addition to standard post-operative care. Endpoints will be surgical complications, fractional decrement in epileptiform discharges from pre- to post-ablation recordings, and surgical outcome at 6 months and one year. Analysis of severe complications will be expressed as a simple complication rate, for overall complications, severe complications, and hemorrhagic complications in specific. The relationship between fractional discharge decrement and outcome will be assessed by regression analysis. Risks of the study will stem from the placement of the stereotactic electrode for intraoperative monitoring, which represents a small incremental risk beyond typical LITT for MTLE.

NCT ID: NCT02912403 Withdrawn - Clinical trials for Normotensive Postpartum Cesarean Section Patients

Ambulatory Blood Pressure and the Normal Increase in Maternal Blood Pressure Postpartum

Start date: August 2016
Phase: N/A
Study type: Observational

Investigators plan to study blood pressure trends on days 3 to 6 of the postpartum period. Investigators will use a home blood pressure monitor that stays on the arm, and takes blood pressures hourly. Participants will record any symptoms that they feel are attributed to high blood pressure and pain medication use.

NCT ID: NCT02912169 Withdrawn - Alzheimer's Disease Clinical Trials

Study to Assess the Safety and Effects of Autologous Adipose-Derived Stromal Cells in Patients With Alzheimer's Disease

Start date: November 1, 2015
Phase: Phase 1/Phase 2
Study type: Interventional

The intent of this clinical study is to answer the questions: 1) Is the proposed treatment safe and 2) Is treatment effective in improving the disease pathology of patients with Alzheimer's Disease and clinical outcomes?

NCT ID: NCT02911961 Withdrawn - Clinical trials for Acetaminophen Exposure

APAP-CYS Protein Adduct Concentrations in Patients With Liver-Directed Therapy Intended to Treat Hepatic Tumors

Start date: August 2021
Phase: Phase 4
Study type: Interventional

The objective of this study is to provide preliminary data to describe serum acetaminophen-cysteine protein adduct (APAP-CYS) concentrations following therapeutic doses of acetaminophen in the setting of non-acetaminophen induced liver injury. This study will utilize hepatic embolization as a model of hepatic injury.

NCT ID: NCT02908386 Withdrawn - Clinical trials for Head and Neck Neoplasms

ROCOCO - Adaptive IMRT Versus IMPT in Head and Neck Cancer

ROCOCO
Start date: November 2015
Phase: N/A
Study type: Observational

Given the lack of evidence for the benefit of particle therapy in relevant cases, he investigators proposed an in silico trial to investigate the dosimetric effect of contour changes for OAR as well as tumor during chemoradiation in H&N patients. Photon and proton-therapy will be compared based on dosimetric data on 7 time points during treatment combined with plan robustness. In that way the investigators will be able to assess and compare the optimal timing for replanning for photon and proton therapy. A database of the University of Pennsylvania (Upenn) consists of 10 patients with head and neck tumors treated with chemo-radiation. Contrast-enhanced CT scans were acquired prior and during RT (T1-T7)